Treatment with the interleukin-12/23 inhibitor ustekinumab or interleukin-23 inhibitors was linked to a lower risk of developing psoriatic arthritis compared with tumor necrosis factor inhibitors.
MDedge News
Treatment with the interleukin-12/23 inhibitor ustekinumab or interleukin-23 inhibitors was linked to a lower risk of developing psoriatic arthritis compared with tumor necrosis factor inhibitors.
MDedge News